Descrizione business
Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng. It has various development product candidates in the areas of oncology, immunology, neuroscience, hematology, ophthalmology, and other diseases.
Consiglio di amministrazione & Consiglio di sorveglianza
| CEO |
| Dr. Osamu Okuda |
| Consiglio di amministrazione |
| Toshiaki Itagaki |
| Consiglio di sorveglianza |
| Dr. Osamu Okuda, Dr. Hisafumi Yamada, Toshiaki Itagaki, Dr. Mariko Y Momoi, Dr. Fumio Tateishi, Hideo Teramoto, Dr. Christoph Franz, Dr. James H. Sabry, Teresa A. Graham |
Dati aziendali
| Name: |
Chugai Pharmaceutical Co., Ltd. |
| Indirizzo: |
1-1 Nihonbashi-Muromachi 2-Chome Chuo-ku,Tokyo 103-8324 |
| Telefono: |
+81-(0)3-3281-6611 |
| Fax: |
+81-(0)3-3281-6607 |
| E-mail: |
-
|
| Internet: |
https://www.chugai-pharm.co.jp/english/index.html |
| Industria: |
Healthcare |
| Settore: |
Pharmaceutical Industry |
| Sub settore: |
- |
| Fine dell'anno finanziario: |
31/12 |
| Flottante libero: |
- |
| Data dell'IPO: |
- |
Rapporti con gli investitori
| Name: |
- |
| IR telefono: |
+81-(0)3-3273-0554 |
| IR Fax: |
+81-(0)3-3281-6607 |
| IR e-mail: |
-
|
